Stephan Foster, PharmD, FAPhA, who is the American Pharmacists' Association liaison to the CDC's Advisory Committee on Immunization Practices sat down with Total Pharmacy at the APHA meeting in March to discuss the use of Prevnar 13 use in adults for the prevention of Streptococcus pneumoniae.
According to the CDC, "the incidence and mortality rate of pneumococcal disease tend to increase after age 50, and these increases are more often seen after age 65.8 The vaccine regimen for individuals older than 65 years involves 2 vaccines: the 23-valent pneumococcal polysaccharide vaccine (PPSV23), Pneumovax, and the 13-valent pneumococcal conjugate vaccine (PCV13), Prevnar."
Transcript
Stephan Foster, PharmD, FAPhA: In 2014, the ACIP made some recommendations to actually add Prevnar 13, a pneumococcal vaccine for the use in adults over the age of 65 along with the caveat that by 2018 we would start looking at whether it was still needed. The incidence of disease has dropped off due to vaccination of the baby so we're evaluating currently whether the policy should be to continue to use that vaccine in adults over the age of 65 or stop it. There's a big debate going on with that right now.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
Pfizer Announces Positive Top-Line Data for Abrysvo Immunization in Adults Aged 18 to 59 Years
April 9th 2024Abrysvo is currently approved to treat RSV-associated lower respiratory tract disease in adults aged 60 years and older, and in infants through the immunization of pregnant individuals.